ABVC (ABVC BioPharma) Cyclically Adjusted FCF per Share: $-1.96 (As of Mar. 2026)


ABVC ABVC BioPharma Inc ABVC
17 GF Score
Price $1.53
GF Value $0.87
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ABVC BioPharma Cyclically Adjusted FCF per Share?

ABVC BioPharma ABVC +6.25% 17 Cyclically Adjusted FCF per Share is $-1.96 as of Mar. 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ABVC BioPharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.035. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.96 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 2.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 60.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 51.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ABVC BioPharma was 79.40% per year. The lowest was 2.90% per year. And the median was 37.75% per year.

As of today (2026-06-28), ABVC BioPharma's current stock price is $1.53. ABVC BioPharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-1.96. ABVC BioPharma's Cyclically Adjusted Price-to-FCF of today is .


ABVC BioPharma  (NAS:ABVC) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ABVC BioPharma Cyclically Adjusted FCF per Share Related Terms


ABVC BioPharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ABVC BioPharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABVC BioPharma Cyclically Adjusted FCF per Share Chart

ABVC BioPharma Annual Data
Trend Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.14 -2.04 -1.98 -1.85 -1.87

ABVC BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.83 -1.98 -2.00 -1.87 -1.96

ABVC vs GRDX, INMB, ALGS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, ABVC BioPharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABVC BioPharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's Cyclically Adjusted Price-to-FCF falls into.


ABVC
17GF Score
ABVC BioPharma Inc ABVC
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABVC BioPharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ABVC BioPharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.035/330.2130*330.2130
=-0.035

Current CPI (Mar. 2026) = 330.2130.

ABVC BioPharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2.443 241.018 -3.347
201609 -0.254 241.428 -0.347
201612 -0.192 241.432 -0.263
201703 -0.732 243.801 -0.991
201706 -0.158 244.955 -0.213
201709 -0.272 246.819 -0.364
201712 -0.094 246.524 -0.126
201803 -0.453 249.554 -0.599
201806 -0.373 251.989 -0.489
201809 -0.177 252.439 -0.232
201812 0.452 251.233 0.594
201903 -0.401 254.202 -0.521
201906 -0.458 256.143 -0.590
201909 -0.127 256.759 -0.163
201912 -0.832 256.974 -1.069
202003 -0.324 258.115 -0.415
202006 -0.727 257.797 -0.931
202009 -0.169 260.280 -0.214
202012 -1.073 260.474 -1.360
202103 -0.579 264.877 -0.722
202106 -0.591 271.696 -0.718
202109 -0.824 274.310 -0.992
202112 -1.006 278.802 -1.192
202203 -1.040 287.504 -1.194
202206 -1.102 296.311 -1.228
202209 -0.159 296.808 -0.177
202212 -0.139 296.797 -0.155
202303 -0.453 301.836 -0.496
202306 -0.272 305.109 -0.294
202309 -0.335 307.789 -0.359
202312 -0.054 306.746 -0.058
202403 -0.098 312.332 -0.104
202406 -0.019 314.175 -0.020
202409 0.005 315.301 0.005
202412 -0.053 315.605 -0.055
202503 -0.036 319.799 -0.037
202506 -0.051 322.561 -0.052
202509 -0.041 324.800 -0.042
202512 -0.024 324.054 -0.024
202603 -0.035 330.213 -0.035

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.96 mean?
ABVC BioPharma (ABVC) has a Cyclically Adjusted FCF per Share of $-1.96 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ABVC BioPharma and its competitors.
Is ABVC BioPharma's Cyclically Adjusted FCF per Share too high?
ABVC BioPharma's current Cyclically Adjusted FCF per Share is $-1.96. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Cyclically Adjusted FCF per Share compare to GRDX and INMB?
ABVC BioPharma's Cyclically Adjusted FCF per Share of $-1.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ABVC BioPharma and its competitors. ABVC BioPharma's current Cyclically Adjusted FCF per Share is $-1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.53 — trading 75.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-1.96. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Cyclically Adjusted FCF per Share is $-1.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABVC BioPharma (ABVC) Overvalued in 2026?

Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued. The current stock price of $1.53 is trading 75.9% above its estimated GF Value™ of $0.87. GuruFocus considers ABVC BioPharma to be Significantly Overvalued.

Key valuation signals for ABVC:

  • Cyclically Adjusted FCF per Share: $-1.96
  • GF Value™: $0.87 vs. price of $1.53 (75.9% above fair value)
  • GF Score™: 17/100 with 1 warning sign

No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ABVC BioPharma Business Description

Address 44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score

Get the complete analysis for ABVC

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.53
Price
$0.87
GF Value